Sun Pharmaceutical Industries has received final USFDA approval for its non-steroid drug BromSite used to treat inflammation and prevent pain in patients undergoing cataract surgery. The drug has been developed by InSite Vision which the company had acquired in November 2015.
The company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016.
As per IMS MAT January 2016, the US NSAID ophthalmic market grew by 8 per cent, generating approximately $400 million in sales and about 4 million prescriptions.
Company Profile : Sun Pharmaceutical Industries Ltd
Leave a Reply